IL6R and COVID-19: Other drugs, recommended by The National Institute of Health (NIH) COVID-19 Treatment Guidelines Panel, to be useful depending on the severity of COVID-19, are baricitinib (an anti-inflammatory biologic for rheumatoid arthritis), tocilizumab (an anti-IL-6R monoclonal immunosuppressive antibody used for autoimmune disorders) and neutralizing SARS-CoV-2 combination monoclonal antibodies, bamlanivimab/etesevimab (Eli Lilly), casirivimab/imdevimab (Regeneron Pharmaceuticals) and sotrovimab (GSK/Vir Biotech) [43] for mild to moderate cases, in particular in the early stages of infection.